Home
drive our discovery
Finch is a clinical-stage microbiome therapeutics company
leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs.
Human-First Discovery platform
Our platform is built to rapidly translate insights mined from compelling human data into the development of novel microbiome therapeutics.
Learn morePipeline
We are developing a pipeline of microbiome therapeutics targeting gastrointestinal diseases and conditions that extend beyond the gut, with a candidate in late-stage clinical development for recurrent C. difficile, and candidates for inflammatory bowel disease, autism spectrum disorder, and chronic hepatitis B in pre-clinical development.
Learn moreRecent news
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference
Finch Therapeutics Appoints Susan E. Graf to Board of Directors
Join us
Join us in our mission to transform the lives of patients and families fighting serious medical conditions.
Learn more